Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Acquiring Company
Immunome Inc.
Acquired Company
Ayala Pharmaceuticals
BothellMonmouth JunctionBiotechnologyHealth CareMedicalTherapeuticsBiotechnologyDescription
Immunome, Inc. has entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. to acquire AL102 and related drug candidate AL101. The acquisition of AL102, a Phase 3 asset for the treatment of desmoid tumors, reinforces Immunome's commitment to developing targeted cancer therapies with best-in-class potential and bringing clinical benefit to underserved patient populations.
Quick answer
Immunome Inc. is acquiring Ayala Pharmaceuticals, announced February 6, 2024. Immunome Inc. is based in Bothell, Washington, United States.
- How much did Immunome Inc. pay for Ayala Pharmaceuticals?
- The deal value was not disclosed.
- What does Immunome Inc. do?
- Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies.
- Where are Immunome Inc. and Ayala Pharmaceuticals based?
- Immunome Inc. is based in Bothell, Washington, United States. Ayala Pharmaceuticals is based in Monmouth Junction, New Jersey, United States.
- Who are the decision-makers at Immunome Inc?
- Fundz holds 2 contacts at Immunome Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio (March 18, 2024)
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (February 16, 2024)
- Novartis completes acquisition of IFM Due to develop first-in-class STING antagonist program targeting innate immune system (March 13, 2024)
- Elevance Health completes acquisition of Paragon Healthcare to enhance specialty medication access (March 11, 2024)
- Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform (February 26, 2024)
- Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio (January 23, 2024)
Who to call at Immunome Inc., and when
When Immunome Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Immunome Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Immunome Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Immunome Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Immunome Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Ayala Pharmaceuticals?
Ayala Pharmaceuticals was acquired by Immunome Inc., based in Bothell. The deal was reported on February 6, 2024. Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Immunome Inc. is publicly traded (IMNM) and operates in Biotechnology.
When did Immunome Inc. acquire Ayala Pharmaceuticals?
Immunome Inc.'s acquisition of Ayala Pharmaceuticals was reported on February 6, 2024. Immunome, Inc. has entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. to acquire AL102 and related drug candidate AL101. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Ayala Pharmaceuticals do?
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is privately held, operating in Biotechnology, and is based in Monmouth Junction.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.